Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 9/20 | 0.37 |
| ▸ | F13A1 | P00488 | 6/20 | 0.37 |
| ▸ | TGM1 | P22735 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | STS | P08842 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17535108 | 0.93 | KIT (0.39) | TGM2F13A1TGM1KITKDM4E | |
| SCHEMBL15586811 | 0.89 | KIT (0.39) | DGAT2TGM2F13A1TGM1KIT | |
| SCHEMBL16035864 | 0.88 | KIT (0.46) | DGAT2KITHTR6 | |
| SCHEMBL16535994 | 0.84 | KIT (0.48) | KITHTR6 | |
| SCHEMBL16536014 | 0.83 | CCNT1 (0.45) | TGM2F13A1TGM1KITKDM4E | |
| SCHEMBL15526002 | 0.79 | RET (0.46) | TGM2F13A1TGM1MEN1KMT2A | |
| SCHEMBL16051682 | 0.79 | KDM4E (0.37) | KDM4EALDH1A1HTTNPSR1PTGDR2 | |
| SCHEMBL16536488 | 0.79 | MMP13 (0.38) | TGM2F13A1TGM1KITKDM4E | |
| SCHEMBL16041258 | 0.78 | SYK (0.40) | TGM2F13A1TGM1KDM4EALDH1A1 | |
| SCHEMBL16039457 | 0.78 | CCNK (0.42) | MMP13STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969375-B2 | CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | ABBIVE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275153-A1 | CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK10 | DGAT2 4588/4885TGM2 3196/4885F13A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.